Literature DB >> 3669498

Serum magnesium level and arterial calcification in end-stage renal disease.

H E Meema1, D G Oreopoulos, A Rapoport.   

Abstract

In this paper we examine the relationship of serum levels of Ca, P, Ca X P, P/Mg, Ca X P/Mg, alkaline phosphatase, and iPTH to the development or regression of peripheral arterial calcifications (AC) in 44 patients with end-stage renal disease being treated by continuous ambulatory peritoneal dialysis (CAPD). The average follow-up time of this longitudinal study was 27 months (range 6-67 months). The patients were divided into two groups: Group A, those showing one or more increases of AC; and Group B, patients in whom AC either did not develop or decreased during the follow-up. There was no significant difference in serum Ca, P, Ca X P, alkaline phosphatase of iPTH between the two groups. However, serum Mg was significantly lower in Group A than in Group B (2.69 +/- 0.52 and 3.02 +/- 0.51 mg/dl, respectively, P less than 0.001), while the ratios P/Mg and Ca X P/Mg were significantly higher. Our observations suggest that in end-stage renal disease hypermagnesemia may retard the development of arterial calcifications.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3669498     DOI: 10.1038/ki.1987.222

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  53 in total

Review 1.  Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease.

Authors:  Jessica Kendrick; Michel Chonchol
Journal:  Semin Dial       Date:  2015-08-17       Impact factor: 3.455

Review 2.  Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication.

Authors:  Sinee Disthabanchong
Journal:  World J Nephrol       Date:  2012-04-06

3.  Magnesium prevents β-glycerophosphate-induced calcification in rat aortic vascular smooth muscle cells.

Authors:  Yaling Bai; Junxia Zhang; Jinsheng Xu; Liwen Cui; Huiran Zhang; Shenglei Zhang; Xunwei Feng
Journal:  Biomed Rep       Date:  2015-05-27

Review 4.  New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

Authors:  Jorge B Cannata-Andía; Minerva Rodriguez-García; Pablo Román-García; Diego Tuñón-le Poultel; Francisco López-Hernández; Diego Rodríguez-Puyol
Journal:  Pediatr Nephrol       Date:  2010-02-12       Impact factor: 3.714

5.  Radiographic manifestations of Mönckeberg arteriosclerosis in the head and neck region.

Authors:  Mehrnaz Tahmasbi-Arashlow; Sevin Barghan; Deeba Kashtwari; Madhu K Nair
Journal:  Imaging Sci Dent       Date:  2016-03-24

6.  Malignant Mönckeberg medial calcific sclerosis.

Authors:  Isabella Pisani; Alessandro De Troia; Landino Allegri; Domenico Corradi; Augusto Vaglio
Journal:  Intern Emerg Med       Date:  2018-01-23       Impact factor: 3.397

7.  Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride.

Authors:  Efstathios Mitsopoulos; Ioannis Griveas; Stavros Zanos; Konstantinos Anagnostopoulos; Anastasia Giannakou; Aikaterini Pavlitou; Georgios Sakellariou
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 8.  Vascular disease in the lower limb in type 1 diabetes.

Authors:  Michael Edmonds
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-02-13

9.  Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis.

Authors:  Faruk Turgut; Mehmet Kanbay; Melike Rusen Metin; Ebru Uz; Ali Akcay; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2008-06-21       Impact factor: 2.370

10.  Long-term proton pump inhibitor use is associated with vascular calcification in chronic kidney disease: a cross-sectional study using propensity score analysis.

Authors:  Maria Fusaro; Marianna Noale; Giovanni Tripepi; Sandro Giannini; Angela D'Angelo; Angelo Pica; Lorenzo A Calò; Davide Miozzo; Maurizio Gallieni
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.